(Q34276476)

1 August 2017

title

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies (English)

1 reference

1 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

1 April 2024

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

1 April 2024

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

1 April 2024

author name string

Kiran Khandke

4

1 reference

1 August 2017

Latha Sridharan

6

1 reference

1 August 2017

Arthur Kunz

7

1 reference

1 August 2017

Boris Gorovits

9

1 reference

1 August 2017

Chandrasekhar Udata

10

1 reference

1 August 2017

Sue Stephens

13

1 reference

1 August 2017

Philip Frost

14

1 reference

1 August 2017

John F. DiJoseph

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Douglas C. Armellino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Erwin R. Boghaert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Maureen M. Dougher

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Philip R. Hamann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Justin K. Moran

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Andrew G. Popplewell

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

Nitin K. Damle

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615373

1 April 2024

language of work or name

English

0 references

publication date

13 November 2003

1 reference

full work available at URL

1 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

1 August 2017

volume

103

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

1807-1814

1 reference

Monoclonal antibody drug conjugates in the treatment of cancer

1 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 April 2024

2

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Toxin-labeled monoclonal antibodies

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Siglecs, sialic acids and innate immunity

1 April 2024

17

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics

1 April 2024

18

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs.

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Expression and Function of CD22, a B-cell Restricted Molecule*

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 April 2024

27

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

1 April 2024

31

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 April 2024

32

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 April 2024

33

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

1 April 2024

34

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

1 April 2024

35

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2466

1 April 2024

Identifiers

1 reference

1 August 2017

1 reference